SPDR S&P Biotech ETF
698 hedge funds and large institutions have $7.55B invested in SPDR S&P Biotech ETF in 2021 Q4 according to their latest regulatory filings, with 139 funds opening new positions, 210 increasing their positions, 198 reducing their positions, and 63 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
698
Holders Change
+66
Holders Change %
+10.44%
% of All Funds
10.78%
Holding in Top 10
20
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.31%
New
139
Increased
210
Reduced
198
Closed
63
Calls
$2.63B
Puts
$3.35B
Net Calls
-$719M
Net Calls Change
+$1.05B
Top Buyers
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$246M |
| 2 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$196M |
| 3 |
Jane Street
New York
|
+$168M |
| 4 |
MCM
Moore Capital Management
New York
|
+$150M |
| 5 |
Goldman Sachs
New York
|
+$138M |
Top Sellers
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$457M |
| 2 |
JPMorgan Chase & Co
New York
|
-$271M |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$221M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$183M |
| 5 |
CAC
Cowen and Company
New York
|
-$50.3M |
